|
For your consideration:
1: J Am Diet Assoc. 2005 Mar;105(3):428-40.
n-3 long-chain polyunsaturated fatty acids in type 2 diabetes: a review. Nettleton JA, Katz R.
ScienceVoice Consulting, Denver, CO 80205, USA. sciencevoice@mindspring.com
Historically, epidemiologic studies have reported a lower prevalence of impaired glucose tolerance and type 2 diabetes in populations consuming large amounts of the n-3 long-chain polyunsaturated fatty acids (n-3 LC-PUFAs) found mainly in fish. Controlled clinical studies have shown that consumption of n-3 LC-PUFAs has cardioprotective effects in persons with type 2 diabetes without adverse effects on glucose control and insulin activity. Benefits include lower risk of primary cardiac arrest; reduced cardiovascular mortality, particularly sudden cardiac death; reduced triglyceride levels; increased high-density lipoprotein levels; improved endothelial function; reduced platelet aggregability; and lower blood pressure. These favorable effects outweigh the modest increase in low-density lipoprotein levels that may result from increased n-3 LC-PUFA intake. Preliminary evidence suggests increased consumption of n-3 LC-PUFAs with reduced intake of saturated fat may reduce the risk of conversion from impaired glucose tolerance to type 2 diabetes in overweight persons. Reported improvements in hemostasis, slower progression of artery narrowing, albuminuria, subclinical inflammation, oxidative stress, and obesity require additional confirmation. Expected health benefits and public health implications of consuming 1 to 2 g/day n-3 LC-PUFA as part of lifestyle modification in insulin resistance and type 2 diabetes are discussed.
1: Biomed Pharmacother. 2002 Oct;56(8):397-406.
N-3 fatty acids and diabetes. Sirtori CR, Galli C.
Department of Pharmacological Sciences, University of Milano, Milan, Italy. cesare.sirtori@unimi.it
Fatty acids of the omega-3 series (n-3 fatty acids) are a well established dietary component affecting plasma lipids (mainly triglycerides) and also major cardiovascular parameters, such as arrhythmogenesis. In view of their peculiar metabolic handling, it has been suggested that they may reduce glucose tolerance in patients predisposed to diabetes. On the other hand, insulin is required for the endogenous synthesis of the long chain n-3 fatty acids from precursors; the heart may thus be particularly susceptible to their depletion in diabetes. This review examines large population studies, carried out particularly by this research group, evaluating the risk of developing glucose intolerance/clearcut diabetes in large series of patients with predisposing conditions. While diabetes development was in no way accelerated in any of these studies, there was, instead, clear evidence of a significant hypotriglyceridemic activity of the supplements. In long-term treatments, there was also a tendency toward a significant reduction of low density lipoprotein (LDL) cholesterolemia, with positive effects on high density lipoprotein (HDL). These findings fit well with cellular changes indicative of improved glucose handling. Finally, recent data suggest an improvement of heart rate variability by fish intake in coronary patients, that is also exerted by the n-3 fatty acids given as ethyl esters, thus providing further indication for the potential benefit of such treatments in diabetic patients.
|